Much has been made about AI’s potential to accelerate drug development timelines while chipping away at its often multi-billion-dollar price tag. But Abraham Heifets, CEO of Atomwise, believes that focusing on efficiency is not necessarily the right measure — or the right conversation — to have. Time for a different conversation “The two ways to…
Eversana partners with AWS to accelerate generative AI in pharma
Life sciences commercial services company Eversana is one of the latest to throw its hat into the generative AI ring. Tapping a partnership with Amazon Web Services (AWS), Everasana is focusing on developing generative AI technologies in the pharmaceutical industry. Also this month, the startup Synthetica Bio announced it would use generative AI to boost…
Rethinking treatment options for patients diagnosed with bipolar 1 disorder
The COVID-19 pandemic has contributed to a significant increase in the rates of Americans living with mental illness.1 Meanwhile, medication shortages and a chronic scarcity of mental health professionals added pressure to an already stressed system.2 In this context, pharma companies play a vital role in developing novel therapies for mental health conditions, which can…
Incorporating real-world evidence into the life cycle of drug development
Utilizing real-world data (RWD) to generate real-world evidence (RWE) is not new and pharmacoepidemiologists have long-standing experience designing and implementing studies utilizing RWE to satisfy regulatory post-marketing safety commitments and to evaluate the effectiveness of drugs. However, RWD and RWE can be used more largely to support the full life cycle of drug development, during…